My current waves on 
MRK
would love some feedback, this catalyst and original chart was brought up originally by @tomikazi
It broke out of the downtrend channel and now is in wave 1.
Has a catalyst on Wednesday 1/20/21
PDUFA VII Decision for MRK's Vericiguat:
Merck Seeks Approval For Heart Failure Drug
Company: Merck & Co., Inc. (NYSE: MRK)
Type of Application: NDA
Candidate: vericiguat
Indication: heart failure
Positive ER expected:
Merck & Co., Inc.'s earnings, with the lowest EPS estimate coming in at $1.32 and the highest estimate coming in at $1.38. Merck & Co., Inc. reported
earnings of $1.16 per share during the same quarter last year, which indicates a positive year over year growth rate of 16.4%. The firm is scheduled to issue
its next quarterly earnings report before the market opens on Thursday, February 4th. -Marketbeat
MRK would love some feedback, this catalyst and original chart was brought up originally by @tomikazi
It broke out of the downtrend channel and now is in wave 1.
Has a catalyst on Wednesday 1/20/21
PDUFA VII Decision for MRK's Vericiguat:
Merck Seeks Approval For Heart Failure Drug
Company: Merck & Co., Inc. (NYSE: MRK)
Type of Application: NDA
Candidate: vericiguat
Indication: heart failure
Positive ER expected:
Merck & Co., Inc.'s earnings, with the lowest EPS estimate coming in at $1.32 and the highest estimate coming in at $1.38. Merck & Co., Inc. reported
earnings of $1.16 per share during the same quarter last year, which indicates a positive year over year growth rate of 16.4%. The firm is scheduled to issue
its next quarterly earnings report before the market opens on Thursday, February 4th. -Marketbeat
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.